Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Women
The New Face of HIV and Treating the 'Hardly Reached'

Physicians, scientists, government agencies, and companies are questioning whether the way they've always recruited for clinical trials still serves patients.

Published
20 July 2019
From
Medscape (requires free registration)
The search for a cure
Is It Safe to Interrupt HIV Treatment During Cure Studies?

Previous research has shown that long interruptions are not safe—but what about shorter, more closely monitored gaps in treatment?

Published
17 July 2019
From
POZ
Retention and linkage to care
Adults with HIV who have compassionate care providers start and remain in treatment longer

Researchers find patients who perceive their primary care providers as lacking empathy and not willing to include them in decision making are at risk for abandoning treatment or not seeking treatment at all.

Published
15 July 2019
From
ScienceDaily
Long-acting HIV treatment
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019

Published
11 July 2019
From
ViiV Healthcare press release
Kidney problems
Analysis Backs New Tenofovir’s Kidney Safety Over Old Version

Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.

Published
11 July 2019
From
POZ
Pharmaceutical industry
GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.

Published
11 July 2019
From
FiercePharma
Long-acting HIV treatment
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV.

Published
10 July 2019
From
Lyndra Therapeutics press release
Transgender people
What the Trans Community Needs to Know About New Expert Recommendations

New provider recommendations aimed at doctors caring for trans patients were published on July 1 in the Annals of Internal Medicine, including changes that overall make it easier to identify trans patients and provide medical care for trans individuals.

Published
08 July 2019
From
The Body
Changing treatment
Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

"Public health (officials) should definitely be aware of the implications of drug resistance mutations conferring resistance to tenofovir and/or lamivudine on the activity, efficacy and durability of DTG in such a country, knowing that at present, individual- level HIV drug resistance testing in low and middle income countries (LMICs) is rare and that data are lacking on DTG use in settings with limited or no viral load monitoring."

Published
07 July 2019
From
Medscape (free registration required)
Achieving the 90-90-90 target
WHO’s “Treat All” Policy Had Immediate Effect on Global HIV Treatment Rates

The World Health Organization (WHO) recommendation in 2015 that all nations provide HIV treatment regardless of an individual’s CD4 count had a rapid and stark effect on increasing rates of rapid access to antiretrovirals (ARVs) in various developing nations.

Published
04 July 2019
From
POZ
← First12345...212Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.